Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. - Adès L; Boehrer S; Prebet T; Beyne-Rauzy O; Legros L; Ravoet C; Dreyfus F; Stamatoullas A; Chaury MP; Delaunay J; Laurent G; Vey N; et al. (Blood, 2009)